• Patients will receive treatment with nivolumab prior to tumor removal for TIL growth. • Surgery and TIL growth ex vivo. • Patients lymphodepleting chemotherapy with cyclophosphamide and fludarabine; TIL infusion; interleukin-2 treatment. • The first six participants will not receive nivolumab prior treatment for comparison. This evidence concerns the gene IL2 and neoplasm.